174 related articles for article (PubMed ID: 31199595)
1. Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Cancer Med; 2019 Aug; 8(9):4169-4175. PubMed ID: 31199595
[TBL] [Abstract][Full Text] [Related]
2. EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.
Hofheinz RD; Lorenzen S; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Tetyusheva M; Heeger S; Vlassak S; Merx K
Ann Oncol; 2018 Apr; 29(4):1010-1015. PubMed ID: 29360920
[TBL] [Abstract][Full Text] [Related]
3. Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer.
Jo JC; Hong YS; Kim KP; Lee JL; Kim HJ; Lee MW; Lim SB; Yu CS; Kim JC; Kim JH; Kim TW
Eur J Dermatol; 2013; 23(1):77-82. PubMed ID: 23238388
[TBL] [Abstract][Full Text] [Related]
4. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
5. Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.
Gaiser MR; Lorenzen S; Merx K; Trojan J; Ocvirk J; Ettrich TJ; Al-Batran SE; Schulz H; Homann N; Feustel HP; Schatz M; Kripp M; Schulte N; Heeger S; Vlassak S; Koch W; Hofheinz RD
Ann Oncol; 2018 Dec; 29(12):2393-2395. PubMed ID: 30307464
[No Abstract] [Full Text] [Related]
6. Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer.
Pinta F; Ponzetti A; Spadi R; Fanchini L; Zanini M; Mecca C; Sonetto C; Ciuffreda L; Racca P
Clin Colorectal Cancer; 2014 Mar; 13(1):62-7. PubMed ID: 24332355
[TBL] [Abstract][Full Text] [Related]
7. Prevention and management of acneiform rash associated with EGFR inhibitor therapy: A systematic review and meta-analysis.
Gorji M; Joseph J; Pavlakis N; Smith SD
Asia Pac J Clin Oncol; 2022 Dec; 18(6):526-539. PubMed ID: 35352492
[TBL] [Abstract][Full Text] [Related]
8. Topical aloe vera for the treatment of cetuximab-related acneiform rash in colorectal cancer: A case report.
Gürbüz M; Akkuş E; Utkan G
J Oncol Pharm Pract; 2021 Mar; 27(2):480-484. PubMed ID: 32623964
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of a Comprehensive Skin Toxicity Program for Patients Treated With Epidermal Growth Factor Receptor Inhibitors at a Cancer Treatment Center.
Yu Z; Dee EC; Bach DQ; Mostaghimi A; LeBoeuf NR
JAMA Dermatol; 2020 Oct; 156(10):1079-1085. PubMed ID: 32609305
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption.
Scope A; Agero AL; Dusza SW; Myskowski PL; Lieb JA; Saltz L; Kemeny NE; Halpern AC
J Clin Oncol; 2007 Dec; 25(34):5390-6. PubMed ID: 18048820
[TBL] [Abstract][Full Text] [Related]
11. Randomized, Double-Blind, Placebo-Controlled Phase Ⅱ Study on the Efficacy and Safety of Vitamin K1 Ointment for Cetuximab or Panitumumab-Induced Acneiform Eruptions-VIKTORIA Study.
Hashimoto H; Iwasa S; Yanai-Takahashi T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Yamazaki N; Kato Y
Gan To Kagaku Ryoho; 2020 Jun; 47(6):933-939. PubMed ID: 32541171
[TBL] [Abstract][Full Text] [Related]
12. Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer.
Dascalu B; Kennecke HF; Lim HJ; Renouf DJ; Ruan JY; Chang JT; Cheung WY
Support Care Cancer; 2016 Feb; 24(2):799-805. PubMed ID: 26184500
[TBL] [Abstract][Full Text] [Related]
13. Dermatux: phase IV trial of Cetuximab plus FOLFIRI in first-line metastatic colorectal cancer receiving a pre-defined skin care.
Schimanski CC; Staib F; Göhler T; Hebart H; Heike M; Neise M; Rudi J; Geer T; Dingeldein G; Lang C; Ehscheidt P; Flohr T; Josten KM; Karthaus M; Schmittel A; Wierecky J; Boller E; Indorf M; Wörns MA; Galle PR; Moehler M
J Cancer Res Clin Oncol; 2017 Jun; 143(6):1023-1034. PubMed ID: 28197787
[TBL] [Abstract][Full Text] [Related]
14. A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash.
Belum VR; Marchetti MA; Dusza SW; Cercek A; Kemeny NE; Lacouture ME
J Am Acad Dermatol; 2017 Sep; 77(3):577-579. PubMed ID: 28807114
[No Abstract] [Full Text] [Related]
15. EGFRI-associated health-related quality of life by severity of skin toxicity in metastatic colorectal cancer patients receiving epidermal growth factor receptor inhibitor target therapy.
Chiang TY; Hsu HC; Jane SW; Chen SC
Support Care Cancer; 2020 Oct; 28(10):4771-4779. PubMed ID: 31974771
[TBL] [Abstract][Full Text] [Related]
16. Reducing Skin Toxicities from EGFR Inhibitors with Topical BRAF Inhibitor Therapy.
Lacouture ME; Wainberg ZA; Patel AB; Anadkat MJ; Stemmer SM; Shacham-Shmueli E; Medina E; Zelinger G; Shelach N; Ribas A
Cancer Discov; 2021 Sep; 11(9):2158-2167. PubMed ID: 33910927
[TBL] [Abstract][Full Text] [Related]
17. Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study.
Rothschild SI; Betticher D; Zenhäusern R; Anchisi S; von Moos R; Pless M; Moosmann P; Popescu RA; Calderoni A; Dressler M; Rauch D; Pederiva S; Woelky R; Papet C; Bühler V; Borner M
Cancer Chemother Pharmacol; 2019 Oct; 84(4):881-889. PubMed ID: 31444619
[TBL] [Abstract][Full Text] [Related]
18. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer.
Fujii H; Iihara H; Suzuki A; Kobayashi R; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
Cancer Chemother Pharmacol; 2016 Jun; 77(6):1209-15. PubMed ID: 27106835
[TBL] [Abstract][Full Text] [Related]
19. Efficacy, tolerability and impact on quality of life of clindamycin phosphate and benzoyl peroxide for the treatment of cetuximab-associated acneiform eruption in patients with metastatic colorectal cancer.
Vaccaro M; Guarneri F; Borgia F; Pollicino A; Altavilla G; Cannavò SP
J Dermatolog Treat; 2016; 27(2):148-52. PubMed ID: 26313697
[TBL] [Abstract][Full Text] [Related]
20. Phytomenadione pre-treatment in EGFR inhibitor-induced folliculitis.
Tomková H; Pospíšková M; Zábojníková M; Kohoutek M; Serclová M; Gharibyar M; Sternberský J
J Eur Acad Dermatol Venereol; 2013 Apr; 27(4):514-9. PubMed ID: 22035385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]